We are live on ! Find out more
SLRN

ACELYRIN

Delisted

SLRN was delisted on the 21st of May, 2025.

101 hedge funds and large institutions have $847M invested in ACELYRIN in 2023 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 20 increasing their positions, 23 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 28

23% more funds holding

Funds holding: 82101 (+19)

6.79% more ownership

Funds ownership: 79.39%86.18% (+6.8%)

13% less funds holding in top 10

Funds holding in top 10: 87 (-1)

13% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 23

44% less call options, than puts

Call options by funds: $3.2M | Put options by funds: $5.7M

47% less capital invested

Capital invested by funds: $1.6B → $847M (-$756M)

Holders
101
Holders Change
+19
Holders Change %
+23.17%
% of All Funds
1.6%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.11%
New
47
Increased
20
Reduced
23
Closed
28
Calls
$3.2M
Puts
$5.7M
Net Calls
-$2.5M
Net Calls Change
-$5.21M
Name Holding Trade Value Shares
Change
Change in
Stake
ACMC
1
AyurMaya Capital Management Company
New Hampshire
$94.9M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$89.9M +$32M +1,505,488 +20%
Citadel Advisors
3
Citadel Advisors
Florida
$57.9M -$2.4M -112,964 -2%
O
4
OrbiMed
New York
$54.2M
OM
5
Opaleye Management
Massachusetts
$42.2M -$265K -12,500 -0.3%
VP
6
venBio Partners
California
$39.2M -$101K -4,760 -0.1%
Vanguard Group
7
Vanguard Group
Pennsylvania
$32.4M +$2.48M +116,847 +4%
JP Morgan Chase
8
JP Morgan Chase
New York
$32.2M -$11.5M -539,247 -15%
IC
9
Ikarian Capital
Texas
$29.7M
GA
10
General Atlantic
New York
$29.4M +$29.5M +1,389,668 +93%
AG
11
Artal Group
Luxembourg
$25.1M +$13.8M +648,065 +36%
SB
12
Samsara BioCapital
California
$24.2M +$2.67M +125,557 +6%
CA
13
CHI Advisors
New York
$23M -$8.51M -400,816 -15%
TCM
14
Tybourne Capital Management
Hong Kong
$22.7M
BlackRock
15
BlackRock
New York
$22.4M +$28.7M +1,350,227 +159%
State Street
16
State Street
Massachusetts
$20.1M +$39.6M +1,863,316 +1,593%
Goldman Sachs
17
Goldman Sachs
New York
$18.1M +$31.2M +1,469,827 +474%
Janus Henderson Group
18
Janus Henderson Group
United Kingdom
$16.4M +$38.1M +1,794,692 New
DCMIC
19
Decheng Capital Management III (Cayman)
Cayman Islands
$15.7M -$130K -6,100 -0.4%
EC
20
EcoR1 Capital
California
$14.3M +$29.8M +1,402,201 New
DCM
21
Driehaus Capital Management
Illinois
$13.4M -$9.33M -439,448 -25%
KCM
22
Kynam Capital Management
New Jersey
$12.2M +$25.5M +1,200,000 New
RI
23
RTW Investments
New York
$9.95M
WP
24
Woodline Partners
California
$9.23M -$2.71M -127,642 -12%
Marshall Wace
25
Marshall Wace
United Kingdom
$9.09M -$5.68M -267,346 -23%

SLRN Hedge Fund Activity: Q3 2023 in Review

101 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in ACELYRIN (SLRN) for Q3 2023, worth a combined $847M — down 47% from $1.6B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new SLRN positions and 28 closed out — a net gain of 19 holders — while 20 added to existing stakes and 23 trimmed.

The largest buyer was State Street, adding an estimated $39.6M. The largest seller was AllianceBernstein, cutting an estimated $23.8M.

  • 101 institutional investors held ACELYRIN (SLRN) as of Q3 2023, up from 82 in Q2 2023.
  • Funds reported $847M of ACELYRIN stock for Q3 2023, down 47% quarter-over-quarter.
  • 47 funds opened new ACELYRIN positions in Q3 2023 and 28 closed out, a net change of +19 holders.
  • The largest ACELYRIN buyer in Q3 2023 was State Street, an estimated $39.6M added.
  • The largest ACELYRIN seller in Q3 2023 was AllianceBernstein, an estimated $23.8M sold.

Based on aggregated 13F filings for Q3 2023.